

**Health Technology Clinical Committee**  
**SBRT and SRS Final Findings and Decision Summary**

**Topic:** Stereotactic body radiation therapy (SBRT) & Stereotactic Radiation Surgery (SRS)  
**Meeting dates:** June 23, 2023 & November 16, 2012  
**Final adoption dates:** July 21, 2023 & March 22, 2013

Coverage determinations for SRS and SBRT were adopted on March 22, 2013 and July 21, 2023, respectively. The below decisions are valid and current.

**SBRT – adopted July 21, 2023**

**Number and coverage topic:**

**20230623A** – Stereotactic Body Radiation Therapy

**HTCC coverage determination:**

SBRT is a **covered benefit with conditions** for treatment of localized prostate cancer, non-small cell and small cell lung cancer, pancreatic adenocarcinoma, oligometastatic disease, hepatocellular carcinoma, and cholangiocarcinoma.

SBRT is **not a covered benefit** for treatment of primary bone, head and neck, adrenal, melanoma, Merkel cell, breast, ovarian, and cervical cancers.

**HTCC reimbursement determination:**

**Limitations of coverage:**

- **Localized Prostate cancer for:**
  - Very low, low, and intermediate risk prostate cancer, as defined by NCCN based on stage, Gleason score, and PSA level, and
  - Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.
- **Non-Small Cell Lung Cancer (NSCLC) for:**
  - Stage I and Stage II (node negative), and
  - Tumor is deemed to be unresectable, or patient is deemed too high risk, or declines operative intervention, and
  - Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.
- **Small Cell Lung Cancer (SCLC) for:**
  - Stage I and Stage II (node negative) and at least one of the following:
    - Tumor is deemed to be unresectable.
    - Patient is deemed too high risk for surgery.
  - Operative intervention declined, and
  - Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.
- **Pancreatic Adenocarcinoma for:**

- Non-metastatic disease and is either deemed not a candidate for induction chemotherapy or has already undergone induction chemotherapy and at least one of the following:
  - Tumor is deemed to be unresectable.
  - Patient is deemed too high risk for surgery.
  - Operative intervention declined.
- AND
- Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.
- **Oligometastatic disease for:**
  - When each of the following conditions are met:
    - Five or fewer total metastatic lesions (maximum 3 per organ)
    - Controlled primary tumor
    - Life expectancy greater than 6 months
  - Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.
- **Hepatocellular carcinoma for:**
  - When each of the following conditions are met:
    - Liver confined disease
    - Five or fewer lesions
    - Life expectancy greater than 6 months
  - Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.
- **Cholangiocarcinoma for:**
  - Non-metastatic disease and at least one of the following:
    - Tumor is deemed to be unresectable.
    - Patient is deemed too high risk for surgery.
    - Operative intervention declined.
  - AND
  - Evaluation includes multidisciplinary team analysis (e.g., tumor board) including a surgical specialist and radiation oncologist.

**Related documents:**

- [Final key questions](#)
- [Final evidence report](#)
- [Meeting materials and transcript](#)

## SRS & SBRT – adopted March 22, 2013

**Number and coverage topic:**

**20121116A** – Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy

**HTCC coverage determination:**

Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy are **covered benefits with conditions** consistent with the criteria identified in the reimbursement determination.

**HTCC reimbursement determination:**

**Limitations of coverage:**

Stereotactic Radiation Surgery (SRS) for Central Nervous System (CNS) primary and metastatic tumors is a covered benefit for adults and children when the following criteria are met:

- Patient functional status score, i.e., Karnofsky score, is greater than or equal to 50; and
- Evaluation includes multidisciplinary team analysis (e.g., tumor board), including surgical input.

Stereotactic Body Radiation Therapy (SBRT) is covered for adults and children for the following conditions when the following criteria are met:

- For cancers of spine/paraspinal structures; or
- For inoperable non-small cell lung cancer, stage 1; and
- Evaluation includes multidisciplinary team analysis (e.g., tumor board), including surgical input.

**Related documents:**

- [Final key questions](#)
- [Final evidence report](#)
- [Meeting materials and transcript](#)

**Agency contact information:**

Agency	Phone Number
Labor and Industries	1-800-547-8367
Public and School Employees Health Plan	1-800-200-1004
Washington State Medicaid	1-800-562-3022